Previous observational studies suggest that oophorectomy substantially reduces breast cancer risk in women with BRCA mutations ( 1 ) and that this association is not abrogated by hormone therapy ( 2 ). In a case -control study of women with deleterious BRCA1 mutations, Eisen et al. ( 3 ) attempt to extend these findings regarding hormone therapy use in postmenopausal BRCA1 mutation carriers. The authors conclude that use of hormone therapy, including combined estrogen plus progestin and estrogen alone, does not appear to be associated with increased risk of breast cancer and may be associated with decreased risk.
Previous observational studies suggest that oophorectomy substantially reduces breast cancer risk in women with BRCA mutations ( 1 ) and that this association is not abrogated by hormone therapy ( 2 ) . In a case -control study of women with deleterious BRCA1 mutations, Eisen et al. ( 3 ) attempt to extend these findings regarding hormone therapy use in postmenopausal BRCA1 mutation carriers. The authors conclude that use of hormone therapy, including combined estrogen plus progestin and estrogen alone, does not appear to be associated with increased risk of breast cancer and may be associated with decreased risk.
This provocative result -especially regarding combined hormone therapy use, which potentially could inform current clinical practice -raises several issues. Are there study design concerns that bring the overall results into question? Historically, how reliable have observational studies been in identifying the infl uence of hormone therapy on breast cancer risk as compared with randomized prospective clinical trials? Are there characteristics of tumors commonly associated with BRCA1 mutations that could afford biologic plausibility to the fi ndings? Finally, what are the current indications for hormone therapy use in general populations and what should they be for women at increased risk of breast cancer?
The study methodology raises two concerns. The case patients and control subjects appear to be drawn from separate populations, and no information on breast cancer detection history is provided. Generally, in case -control analyses, case patients are identifi ed in a given population and then matched to control subjects in the same population. In the current analysis, the authors state that in most cases germline mutation testing was initially offered to women who were diagnosed with breast or ovarian cancer. However, limited information is provided regarding how the control population with BRCA1 mutations was identifi ed. We are told that family members were offered BRCA mutation testing after a proband who was diagnosed with breast cancer and had a BRCA mutation. However, it is unclear what proportion of the control subjects were family members of the case patients. How many of the control subjects were unrelated health care conscious individuals who were perhaps more likely to adhere to breast cancer detection programs than the general population and the comparison group? The similar number of relatives with breast cancer in case patients and control subjects suggests that most control subjects were recruited for reasons other than family history. Regardless, the described methodology suggests that separate and perhaps disparate populations were used to identify case patients and control subjects. Thus, differences in screening patterns and study populations provide a potential alternative explanation for study fi ndings.
In several respects, results from observational studies that evaluate use of estrogen plus progestin and estrogen alone in postmenopausal women that are performed in the general population have been at odds with those from randomized clinical trials. The preponderance of observational studies suggest that estrogen plus ( 4 ) . In the Women's Health Initiative (WHI) trial that evaluated conjugated equine estrogen plus medroxyprogesterone acetate vs placebo for women with an intact uterus, breast cancer incidence was higher with hormone therapy but the cancers were larger and in a more advanced stage; the frequency of mammograms with abnormalities and breast biopsies was also higher, with both detecting breast cancers less reliably ( 5 , 6 ) . With respect to use of estrogen alone, most older observational studies reported a modest increase in breast cancer risk with estrogen use ( 7 ) . In contrast, the WHI randomized trial that evaluated conjugated equine estrogens for women with prior hysterectomy reported no increase in breast cancer incidence with estrogen use vs placebo, with a trend to a decreased risk ( 8 ) .
Menopausal Hormone Therapy in BRCA1 Mutation Carriers: Uncertainty and Caution
The issue of therapy related to premature menopause and climacteric symptoms represents a substantial problem in women who have early-stage resected breast cancer. In this setting, a metaanalysis of observational studies ( 9 ) suggested that hormone therapy could be administered safely and would not increase risk of breast cancer recurrence. However, when three randomized trials were conducted, two demonstrated a substantial and statistically signifi cant increase in breast cancer recurrence with hormone therapy ( 10 -12 ), prompting editorials challenging the ability of observational studies to address such questions ( 13 , 14 ) . Given this history, the suggestion of safety of hormone therapy, especially of combined estrogen plus progestin, in women with BRCA1 mutations that is based on a single observational study requires extremely cautious interpretation.
The authors correctly recognize that a substantial body of evidence relates use of combined estrogen plus progestin to increased risk of breast cancer, including the recent dramatic reduction in hormone receptor -positive breast cancer seen among 50-to 69-year-old US women following the publication of the WHI combined hormone therapy results ( 15 ) and the subsequent decrease in hormone therapy use ( 16 ) . However, there is a basis for at least a null fi nding for estrogen plus progestin infl uence on breast cancer risk in BRCA1 mutation cancers. Because BRCA1 -associated breast cancers are commonly negative for estrogen and progesterone receptors ( 17 ) , they are potentially less likely to be under hormonal infl uence. The apparent paradox of reduction in breast cancer risk following oophorectomy in BRCA1 mutation carriers has been addressed in preclinical studies that suggest that BRCA1 alters the response of breast cancer cells to antiestrogen therapy by directly modulating estrogen receptor ␣ expression ( 18 ) , leading to a hypothesis that these tumors follow a pathway in which hormone stimulation is required early followed by loss of hormone receptors later. Finally, the apparent association between relatively short-term use of estrogen plus progestin and lower breast cancer incidence could represent a false-positive fi nding because in the WHI randomized trial, combined hormone use was associated with fewer breast cancers during the fi rst several years, a fi nding that was likely related to interference with breast cancer detection rather then a true reduction in incidence ( 6 ) .
In summary, the results presented by Eisen et al. (3) regarding hormone therapy use in postmenopausal BRCA1 mutation carriers provide some evidence for safety but are insuffi cient to reliably inform routine clinical practice. Decision making regarding menopausal therapies in women at increased risk of breast cancer is complex ( 19 ) . The current regulatory agency label identifi es climacteric symptoms as the main indication of hormone therapy use at the lowest dose and shortest duration consistent with therapeutic goals. How many postmenopausal women with BRCA1 mutations have limiting symptoms of hot fl ashes, vaginal/vulvar problems, and sexual dysfunction that cannot be addressed using nonhormonal approaches, and what should be the defi nition of the term "limiting" providing a threshold for hormone use? To address these issues, the editorial comments of Garber and Hartman of 4 years ago ( 20 ) are still true today: "many aspects of the effects of 'menopausal hormone therapy ' on breast cancer risk in mutation carriers are unknown." As a result, continued caution in prescribing hormone therapy to women with BRCA1 mutations who are at high risk for breast cancers remains prudent.
